Background Eosinophils contribute to the pathogenesis of multiple diseases, including asthma. Treatment with antibodies targeting IL-5 or IL-5 receptor a reduces the frequency of asthma exacerbations. Eosinophil receptors for IL-5 share a common ß-chain with IL-3 and GM-CSF receptors. We recently reported that IL-3 is more potent than IL-5 or GM-CSF in maintaining the ERK/p90S6K/RPS6 ribosome-directed signaling pathway, leading to increased protein translation. Objective We aimed to determine disease-relevant consequences of prolonged eosinophil stimulation with IL-3. Results Human blood eosinophils were used to establish the impact of activation with IL-3 on IgG-driven eosinophil degranulation. When compared to IL-5, continuing exposure to IL-3 further induced degranulation of eosinophils on aggregated IgG via increased production and activation of both CD32 (low affinity IgG receptor) and aMß2 integrin. In addition, unlike IL-5 or GM-CSF, IL-3 induced expression of CD32B/C (FCGRIIB/C) subtype proteins, without changing CD32A (FCGRIIA) protein and CD32B/C mRNA expression levels. Importantly, these in vitro IL-3-induced modifications were recapitulated in vivo on airway eosinophils. Conclusions and Clinical Relevance We observed for the first time upregulation of CD32B/ C on eosinophils, and identified IL-3 as a potent inducer of CD32-and aMß2-mediated eosinophil degranulation.
Introduction
Asthma exacerbations are often associated with eosinophilic airway inflammation, and therapies targeting eosinophils (EOS) decrease the frequency of asthma exacerbations [1] . The molecular events that link airway eosinophils with asthma exacerbations are not fully known but probably involve eosinophil release of toxic granule proteins (including eosinophil cationic protein/ ECP and eosinophil-derived neurotoxin/EDN) and inflammatory mediators (cytokines and chemokines).
Blood or airway eosinophilia defines a major asthma phenotype. Most of the patients with this phenotype control their disease with inhaled corticosteroids, while a subset of patients with severe eosinophilic asthma have little or no response to high doses of inhaled corticosteroids, and are candidates for eosinophil-targeted anti-IL-5 therapies [2] . IL-5 is a cytokine that is critical for eosinophil development, survival and functions. Treatments with monoclonal antibodies targeting IL-5 dramatically reduce circulating eosinophils and decrease the frequency of asthma exacerbations in severe asthmatic subjects with eosinophilia [3, 4] . However, the effect on lung tissue eosinophils is much less pronounced compared to blood [5] . Because IL-5, GM-CSF and IL-3 signal via a common b-chain receptor and therefore possess many redundant functions [6, 7] , blocking one cytokine may not mitigate all their effects on eosinophil functions. Importantly, in addition to the redundancy among these cytokines, each cytokine-specific a-chain receptor can signal via separate signalling pathways. In fact, GM-CSF and IL-5 can impact cell survival in a b-chain-independent manner [8] [9] [10] . Also, these cytokines can differentially regulate their receptors, with IL-5 and IL-3 decreasing and increasing, respectively, their specific a-chain receptor [11] [12] [13] . We and others have demonstrated that compared to IL-5 or GM-CSF, IL-3 is a more potent inducer of certain eosinophil functions, including cell surface expression of CD48 [14] , aminopeptidase N (CD13) [15] , ICAM-1 (CD54) [16] , activin-A [17] , metalloproteinase-9 [18] , thymic stromal lymphopoietin receptor [19] and semaphorin 7A [20] . More recently, we found that unlike GM-CSF and IL-5, IL-3 maintains intracellular signalling via the ERK/p90S6K/RPS6 pathway for > 24 h, which leads to increased protein translation of semaphorin 7A [12] . Notably, IL-3 maintains signalling in basophils leading to production of proteins otherwise not induced by IL-5 or GM-CSF [21] .
IL-3 is relevant in allergy as it is released by activated Th-2 lymphocytes and by mast cells and basophils following IgE cross-linking [22] . In asthma, polymorphisms in the IL-3 gene have been associated with disease development [23, 24] . In addition, IL-3 is elevated in serum in poorly controlled asthmatic patients, and airway IL-3-positive cells are increased with asthma severity [25, 26] . Furthermore, segmental allergen challenge in mild asthma leads to elevated levels of IL-3 in the BAL fluid [20, 27] , and while airway eosinophils display reduced surface a-chain for the IL-5 receptor, they show increased IL-3 receptor compared to blood eosinophils [12, 28] .
Eosinophil-driven pathology involves the release (degranulation) of preformed toxic granule proteins and mediators of inflammation. A prolonged effect of IL-3 vs. IL-5 or GM-CSF on eosinophil degranulation has not been reported. High amounts of IgG are present in human BAL fluid [29] , and allergenspecific IgG correlates with EDN in sputum of asthmatic patients [30] . Therefore, antigen-bound or aggregated IgG has been used as a relevant model to investigate eosinophil degranulation [31, 32] . In these studies, the low-affinity IgG receptor II, CD32 (FCGRII) [32] , and aMb2 integrin (CD11b/CD18) [31] were reported to be responsible for eosinophil degranulation on IgG.
Therefore, in this study, we analysed the effect of prolonged IL-3 activation on CD32 and the aMb2 integrin level and activation states and their function on IgG-induced eosinophil degranulation.
Materials and methods

Reagents
Recombinant human (Rh) GM-CSF was purchased from R&D Systems Inc (Minneapolis, MN, USA), while rhIL-3 and rhIL-5 were purchased from BD Biosciences (San Jose, CA, USA). Human serum IgG was from SigmaAldrich (St. Louis, MO, USA), LY294002 from Cell Signaling (Danvers, MA, USA), and BI-D1870 and PF-4708671 from Selleckchem (Houston, TX, USA). For the neutralization of IL-3-activated eosinophil degranulation on aggregated IgG, polyclonal goat anti-FCGRIIB/C and anti-FCGRIIA antibodies and control goat IgG were from R&D systems. Neutralizing anti-aM/CD11b (mouse, clone 2LPM19c) was from Biomeda (Foster City, CA, USA), anti-b1 integrin (rat, clone mAb13) was from Sigma, and the anti-b7 (rat, clone Fib504) was from BD Biosciences. The control mouse IgG 1 and the control rat IgG2a were from Dako (Carpinteria, CA, USA) and Santa Cruz Biotechnologies (Dallas, TX, USA), respectively. All the neutralizing anti-integrin antibodies have been described previously [33] .
Subjects, cell preparations and cultures
The study protocol was approved by the University of Wisconsin-Madison Health Sciences Institutional Review Board. Informed written consent was obtained from subjects prior to participation. For studies of in vitro eosinophil activation, peripheral blood eosinophils were obtained from allergic subjects with and without mild asthma. Subjects with prescriptions for low doses of inhaled corticosteroids did not use their corticosteroids the day of the blood draw. Eosinophils were purified by negative selection as previously described [20] . Briefly, heparinized blood was diluted 1 : 1 in HBSS and was overlaid above Percoll (1.090 g/mL). After centrifugation at 700 g for 20 min at room temperature, the mononuclear cells were removed from the plasma/percoll interface and erythrocytes were eliminated from the cell pellet by hypotonic lysis. The remaining pellet was resuspended in 2% NCS in HBSS. Cells were then incubated with anti-CD16, anti-CD3, anti-CD14 and anti-glycophorin-A beads from Miltenyi (San Diego, CA, USA), and run through an AutoMACS (Miltenyi). Eosinophil preparations with purity > 99% and viability~98% were used the same day,~5 h after the blood draw.
For studies of in vivo eosinophil activation, bronchoscopy and bronchoalveolar lavage (BAL) were performed 48 h after segmental bronchoprovocation with an allergen (SBP-Ag) in subjects with mild asthma who were allergic to ragweed, dust mite, or cat dander allergens [20] . Eosinophils were purified, as previously described [12] , from the BAL cell preparation (BAL EOS) and from peripheral blood (BBL EOS) of the same allergen-challenged subject. On the same day, eosinophils were also purified from peripheral blood of a control unchallenged subject (control EOS (Ctrl)).
Flow cytometry
Blood eosinophils were activated with IL-3 (2 ng/mL), IL-5 (4 ng/mL) or GM-CSF (2 ng/mL), or cultured without cytokine (Resting) for 20 h and then stained for flow cytometric analysis. PE-conjugated anti-CD32 (FCGRII) (clone FUN-2) was from Biolegend (San Diego, CA, USA), FITC-conjugated anti-CD64 (FCGRIclone 10.1), FITC-conjugated anti-CD16 (FCGRIII-clone 3G8), PE-conjugated anti CD11b (aM-clone D12), FITC-conjugated anti-CD18 (b2-clone L130) and corresponding isotype controls, PE-and FITC-conjugated mouse IgG 1 were all from BD Biosciences. The activation state of CD32 was measured using the previously described monoclonal phage antibody A17 [34, 35] . Activation-sensitive anti-aM CBRM1/5 was from BioLegend and anti-b 1 N29, from Chemicon/Millipore/ Sigma-Aldrich [36] . PE-conjugated goat anti-mouse Ab was used as the secondary Ab. Five to 10 thousand viable (no propidium iodide uptake) cells were acquired on a FACSCalibur (BD Biosciences). Data were analysed with FlowJo (TreeStar Inc., Ashland, OR, USA).
Real-time PCR
Total RNA was extracted from eosinophils using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Reverse transcription reaction was performed using the Superscript III system (Invitrogen/Life Technologies, Grand Island, NY, USA). mRNA expression was determined by real-time quantitative PCR (RT-qPCR) using SYBR Green Master Mix (SABiosciences, Frederick, MD, USA) and Applied Biosystems 7500 Sequence detector (ABI/Invitrogen, Carlsbad, CA, USA) as previously described [37] . Specific primers shown in the Table S1 were designed using Primer Express 3.0 (Applied Biosystems) and blasted against the human genome to determine specificity using http://www.ncbi.nlm.nih.gov/tools/primer-blast. The housekeeping gene, b-glucuronidase (GUSB, forward: CAGGACCTGCGCACAAGAG, reverse: TCGCA-CAGCTGGGGTAAG), was used to normalize the samples. Standard curves were performed and efficiencies were determined for each set of primers. Efficiencies ranged between 94% and 99%. Data are expressed as fold change using the comparative cycle threshold (ΔΔCT) where ΔCt = Ct target gene (FCGRIIA or FCGRIIB or FCGRIIC) -Ct of the housekeeping gene (GUSB); ΔΔCT = ΔCT after cytokine treatment -ΔCT of eosinophils at 0 h; and fold change = 2
ÀΔΔCt [38] .
Western blot
Cells were lysed either in RIPA buffer (Cell Signaling) plus 0.2% SDS and protease inhibitors, or directly in Laemmli buffer (10% SDS), before boiling and loading onto 10-12% SDS-polyacrylamide gels. Immunoblot analysis was performed as previously described [12] using rabbit polyclonal anti-FCGRIIA antibody (GeneTex, Irvine, CA, USA), rabbit monoclonal anti-FCGRIIB/ C (Sino Biological Inc., North Wales, PA, USA), mouse monoclonal anti-FCGRIII antibody (MEM-154; Invitrogen) and mouse monoclonal anti-b-actin (SigmaAldrich). Secondary HRP-conjugated anti-rabbit IgG antibody and anti-mouse IgG were from Pierce/Thermo Fisher Scientific (Rockford, IL, USA). Immunoreactive bands were visualized with Super Signal West Femto chemiluminescent substrate (Pierce/Thermo Fisher Scientific). Bands were quantified using the FluorChem â Q Imaging System (Alpha Innotech/ProteinSimple, Santa Clara, CA, USA), and data are expressed as a ratio of target to b-actin.
Total cellular EDN measurement and degranulation on heat-aggregated IgG (HA-IgG)
Peripheral blood eosinophils were cultured at 1 9 10 6 / mL in medium (RPMI 1640 plus 10% fetal bovine serum), without cytokine (resting), or with IL-3 (2 ng/mL), or with IL-5 (4 ng/mL) for 20 h. Eosinophils were then lysed with 50 mmol/L HCl and 0.5% Triton X-100 to release total granule contents [39] or added to plates treated with heat-aggregated IgG to assess degranulation. Heat aggregation of human IgG (HA-IgG) was performed in PBS for 30 min at 63°C as previously described [40] . After 20-h cultures with or without cytokines, cells were washed and suspended at 1 9 10 6 /mL in fresh medium (no cytokine), and 100 lL was added to a 96-well plate, which had been coated overnight with or without HA-IgG or monomeric IgG (both at 10 lg/mL; 50 lL/well) and saturated with 0.1% gelatin for 30 min at 37°C. After a 6-h incubation, photomicroscopy was performed (digital camera and microscope, both from Olympus) and supernatant fluids were analysed by ELISA for EDN release. Human EDN ELISA (MBL, Woburn, MA, USA) has a minimum detection limit of 0.62 ng/mL. For the neutralization experiments, IL-3-activated peripheral blood eosinophils were pretreated with the neutralizing antibodies 15 min before their incubation on HA-IgG. Degranulation of BAL EOS on HA-IgG was performed using freshly prepared (no culture) cells.
Statistical analyses
Statistical analyses were performed using the SigmaPlot 11.0 software package (Systat Software, Inc., San Jose, CA, USA). Differences between two groups were analysed using the paired Student's t-test. One-Way ANOVA was used to compare more than two groups, and P < 0.05 was considered statistically significant.
Results
Flow cytometric analysis of eosinophils cultured without or with IL-3 (2 ng/mL), IL-5 (4 ng/mL) or GM-CSF (2 ng/mL) for 20 h (Fig. 1a) indicated that eosinophils do not express surface CD16 or CD64. However, CD32 was present on resting eosinophils' surface and was increased by cytokine activation (Fig. 1a) . Figure 1b shows that IL-3 enhanced surface CD32 more potently than did IL-5.
CD32 comprises three different genes: FCGRIIA, FCGRIIB and FCGRIIC. To learn whether any of these three genes is (are) differentially regulated by IL-3, IL-5
and GM-CSF, we analysed their expression level over time following activation by the three cytokines (Fig. S1 ). All three gene messengers (FCGRIIA, FCGRIIB and FCGRIIC) were readily detectable in freshly isolated eosinophils by real-time PCR (Fig. S1) (Fig. S1) , which then partially decreased at 20 h (not shown).
Eosinophil lysates were immunoblotted with antibodies that specifically recognize FCGRIIA and FCGRIIB/C (Fig. 2) . At the protein level, cellular FCGRIIA was detected in resting eosinophils and there was a slight apparent increase of FCGRIIA by IL-3-, IL-5-or GM-CSF-treated eosinophils compared to cells cultured without cytokine, although statistical significant differences were not reached (Fig. 2a) . In contrast, FCGRIIB/C proteins were up-regulated more than 15-fold by IL-3 compared to no cytokine and more than fourfold compared to IL-5 or GM-CSF (Fig. 2b) . IL-3-induced FCGRIIB/C proteins was observed between 20 h and 44 h, while IL-5 or GM-CSF failed to significantly induce FCGRIIB/C at any time-points between 1 h and 44 h (Figs S2 and 2) . The strong increase of FCGRIIB/C proteins and the lack of change at the mRNA levels implicate control at the level of translation. We recently reported that semaphorin 7A protein, but not mRNA, is IL-3-up-regulated in eosinophils by a pathway that requires 90-KDa ribosomal S6 kinase (p90S6K) [12] . Similarly, Fig. 2b shows that the p90S6K inhibitor (BI-D1870) completely blocked IL-3-induced FCGRIIB/C production, whereas the inhibitors of the p70 ribosomal S6 kinase (PF-4708671) and PI3K (LY294002) had no effect. These data suggest that FCGRIIB/C is upregulated at the translational level by IL-3 via the p90S6K, similarly to semaphorin 7A. Of note, FCGRIII (CD16) protein was not detected by Western blot in eosinophils under any of our culture conditions (not shown).
CD32 binds complexed IgG; therefore, eosinophil degranulation on heat-aggregated (HA)-IgG was analysed. Figure 3a shows total EDN present in eosinophils cultured with IL-3, IL-5 or without cytokine for 20 h. Figure 3b indicates that eosinophils pre-activated with IL-3 for 20 h and then seeded on HA-IgG for 6 h released EDN to a concentration of~800 ng/mL, which was > 2.5-fold higher than EDN release by IL-5-activated eosinophils (Fig. 3b) . Of note, 800 ng/mL corresponds to~25% of total cellular EDN (Fig. 3a) which is in line with EDN release to the frequently reported eosinophil degranulation activator, fMLP that typically induces release of around 20% of total EDN [39] . Unlike HA-IgG, and in agreement with Kaneko et al. [31] , the monomeric IgG coated at the concentration of 10 lg/mL did not significantly induce EDN degranulation (Fig. 3b) . The slight increase in EDN release from cells not exposed to cytokine or IgG was possibly due to cell death after the 20-h priming and during the incubation on IgG or no IgG, as we have previously shown that resting eosinophils started dying when cultured for more than 24 h, reaching~50% death at 48 h [12] and (Fig. S3) . Figure 3c illustrates adhesion and spreading of IL-3-activated eosinophils on HA-IgG after 6 h. Figure 4 shows the inhibition of IL-3-activated eosinophil degranulation with anti-FCGRIIB/C (10 lg/mL) or anti-aM integrin (1 lg/mL) antibodies. The inhibition of degranulation with anti-FCGRIIA (10 lg/mL; Fig. 4 ) was somewhat unexpected as IL-3 did not increase FCGRIIA production (Fig. 2) . The inhibition suggests that IL-3 possibly enhanced the activation state of FCGRIIA rather than its production. Of note, according to the neutralizing antibody's provider (R&D Systems), the cross-reactivity of the anti-FCGRIIA antibody with FCGRIIB was less than 5%, indicating it is unlikely that the anti-FCGRIIA cross-reacted with FCGRIIB/C under our conditions. Thus, we analysed the activation state of CD32 by flow cytometry using the A17 phage antibody [34, 35] . Figure 5a shows that, unlike IL-5, long-term (20-h) activation with IL-3 increased CD32 activation on eosinophils.
The amount of surface aM and b2 on eosinophils was also augmented following activation with IL-3 for 20 h (Fig. 5b) , and there was increased expression of the highly active conformation of aMb2 IL-3-activated, compared to resting or IL-5-activated, eosinophils (Fig. 5c) . Conversely, staining with N29, which recognizes the intermediate-and high-activity state of b1 [41] , tended to decrease on cytokine-activated eosinophils, although differences did not reach statistical significance (Fig. 5c) . Collectively, these data indicate that IL-3 induces prolonged surface expression and activation of both CD32 and aMb2 integrin.
To evaluate the in vivo relevance of these in vitro data, we analysed airway eosinophils (BAL EOS) obtained by bronchoscopy 48 h after a segmental allergen challenge. Because we have reported that BAL EOS display more activated CD32 [34] and aMb2 [36] integrin compared to blood eosinophils, we analysed whether BAL EOS display increases in both degranulation on HA-IgG and expression of FCGRIIB/C, compared to blood eosinophils. Freshly isolated BAL EOS were seeded on HA-IgG for 4 h, and EDN released in the cell supernatant fluids was measured by ELISA. As shown on Fig. 6a , BAL EOS demonstrated greater degranulation compared to blood eosinophils in the presence of coated HA-IgG. In addition, BAL EOS produced a higher amount of FCGRIIB/C compared to both control blood Fig. 4 . Neutralizing antibodies anti-FCGRIIB/C, anti-FCGRIIA and antiaM integrin strongly reduce IL-3-activated eosinophil degranulation on HA-IgG. Blood eosinophils were activated with IL-3 (2 ng/mL) for 20 h and were treated with the indicated antibodies for 15 min before the incubation on HA-IgG (10 lg/mL) for 6 h. The anti-FCGRII antibodies (anti-FCGRIIA or anti-FCGRIIB/C) and goat IgG were used at 10 lg/mL, and the other antibodies were used at 1 lg/mL. EDN release was measured by ELISA. * and # indicate a significant decrease compared to goat and mouse IgG, respectively (P < 0.04 for all paired comparisons, paired t-test; n = 4 experiments with four different donors).
eosinophils and blood eosinophils from the allergenchallenged subjects (BBL EOS) (Fig. 6b) . Altogether, these data indicate that after allergen challenge, airway eosinophils have a similar phenotype to blood eosinophils activated ex vivo with IL-3.
Discussion
In the light of our recent findings that IL-3 is unique among the three b-chain cytokines in its ability to increase translation of semaphorin 7A by maintaining p90S6K/RPS6 intracellular signalling [12] , the current report demonstrates that while the b-chain cytokines have many overlapping functions, IL-3 exhibits a clear distinction when it comes to CD32-mediated degranulation.
In here, we demonstrate that unlike IL-5 or GM-CSF, activation of eosinophils with IL-3 induced prolonged CD32 and aMb2 surface expression and activation, leading to eosinophil degranulation on immobilized and aggregated IgG. Moreover, while FCGRIIA protein amount remained largely unaffected by eosinophil activation, we showed that FCGRIIB/C on eosinophils was up-regulated as a result of sustained IL-3-mediated activation and prolonged activity of the p90S6K.
We have recently reported that unlike IL-5 and GM-CSF, IL-3 maintains p90S6K-dependent RPS6 phosphorylation in eosinophils, leading to semaphorin 7A protein production [12] . We now show that IL-3-driven FCGRIIB/C protein production is also dependent on p90S6K. Interestingly, sustained intracellular signalling and RPS6 phosphorylation exclusively downstream of IL-3 has been recently shown in basophils as well [21] . Although, the function of RPS6 in its phosphorylated state remains uncertain, Roux et al. [42] have demonstrated that the activation of the Ras/ERK/p90S6K/RPS6 pathway stimulates cap-dependent translation. It is possible that this pathway also controls translation of FCGRIIB/C in IL-3-activated eosinophils. Taken together, IL-3-induced prolonged signalling, and, consequently, production of important specific proteins in basophils and eosinophils, suggests that IL-3 may support some of the disease-associated functions of these granulocytes. (a-c) Graphs show box plots depicting medians and interquartile ranges between the 25th and 75th percentiles of surface proteins for three or four experiments with different donors, and y-axes are specific geometric mean channel fluorescence (gMCF). * indicates significant difference between IL-3 and IL-5 (P < 0.001 for A17, P = 0.009 for CD11b, P = 0.021 for CD18, P = 0.036 for CBRM1/5; paired t-test).
The modest degranulation of IL-3-activated eosinophils on monomeric compared to aggregated IgG under our conditions suggested the involvement of a low-affinity receptor for IgG rather than a high-affinity receptor like CD64. In accordance with precedent quantitative proteomic and RNAseq analyses [43, 44] , we did not detect FCGRI (CD64) nor FCGRIII (CD16) on eosinophils. Therefore, CD32 was most likely the candidate that could trigger the interaction with aggregated IgG. The requirement of CD32 for eosinophil degranulation on IgG is in agreement with several studies. Kaneko et al. [31] reported eosinophil degranulation in a CD32-dependent manner when in contact with antigen-IgG1 or antigen-IgG3 complexes. This was later confirmed in another model where immune complexes of the four IgG subclasses (IgG 1-4) could trigger eosinophil degranulation [32] .
The low-affinity receptor for IgG, CD32, is a type I trans-membrane glycoprotein expressed by granulocytes, macrophages/monocytes and platelets. The constitutive presence of CD32 on the eosinophil surface is well known [45, 46] ; however, in humans, three different genes code for CD32: CD32A (FCGRIIA), CD32B (FCGRIIB) and CD32C (FCGRIIC). Although FCGRIIA is a well-known membrane protein present on eosinophils and neutrophils, we show for the first time up-regulation of FCGRIIB/C protein on human eosinophils, exclusively after long-term (20 h) activation with IL-3. Munitz et al. [47] had previously shown the presence of a high level of surface FCGRIIB on blood eosinophils, although no data on the used antibody was described in this study. Therefore, it is uncertain whether the antibody used in this previous study was specific for FCGRIIB, particularly as the extracellular and membrane parts of the three proteins are highly homologous (> 95%) and these portions of FCGRIIB and FCGRIIC are 100% identical. Interestingly, our results implicate both FCGRIIA and FCGRIIB/C in IL-3-induced eosinophil degranulation on IgG. The intracellular tails are much less similar (~25%) than the extracellular portions, with FCGRIIB containing an immunoreceptor tyrosine-based inhibitory motif (ITIM), while FCGRIIA and FCGRIIC contain identical tyrosine-based activating motifs (ITAM) [48] . Therefore, while FCGRIIA and FCGRIIC can trigger signal transduction through their ITAM, FCGRIIB and its ITIM triggers an inhibitory intracellular signal. Consequently, it is very likely that the inhibition of IL-3-induced degranulation using the neutralizing anti-FCGRIIB/C antibody occurs via FCGRIIC rather than FCGRIIB. We did not investigate whether IL-3 induces solely FCGRIIB or FCGRIIC or both. However, due to the high level of both FCGRIIB and FCGRIIC mRNAs in resting eosinophils, and the similarity of their 5 0 untranslated region, it is likely that IL-3-activated eosinophils produce both proteins.
Another novel observation is the ability of IL-3 to maintain the activation state of CD32 on eosinophils in vitro. CD32 activation state was measured using the phage A17, an anti-active CD32 antibody, which was previously utilized to demonstrate both eosinophil priming in vivo in asthmatic subjects [35] , and the activation state of airway eosinophils [34] . The association between CD32 activation state and IL-3-induced eosinophils degranulation suggests that activated CD32 plays a role in eosinophil degranulation. Of note, the presence of A17 staining on a small population of in vitro nonactivated eosinophils from our allergic population may indicate that some circulating eosinophils from these subjects display a CD32 active state in vivo, which persists during the 20-h culture. This is in agreement with a previous study that reported higher CD32 activation state on eosinophils from asthmatic vs. healthy subjects [35] . Notably, the A17 antibody recognizes activated FCGRIIA [34, 35] but its interaction with activated FCGRIIB/C is unknown. 
